On November 5, Tianjin Medical Products Administration (TJMPA) met at CanSino Biologics Inc. (CanSinoBIO) with a delegation led by Prof. Taruna Ikrar, the Chairperson of Indonesian FDA (BPOM), and held talks with CanSinoBIO and Indonesian biopharmaceutical company Etana.

Zhang Shengxi, Deputy Director of the Tianjin Medical Products Administration, noted that this meeting represents a practical step under the cooperation framework between China’s National Medical Products Administration (NMPA) and the Indonesian BPOM, through which the Tianjin Medical Products Administration aims to strengthen regulatory collaboration and exchange on vaccine development and expedite vaccine registration processes in both countries, while fostering closer communication and partnership between Chinese and Indonesian biopharmaceutical companies on vaccine technology transfer and quality standards to support the development of safer and more effective vaccines.

During the meeting, officials from Tianjin Medical Products Administration outlined China’s regulatory framework for drug registration and the responsibilities of provincial regulatory authorities. They also highlighted CanSinoBIO’s successful transformation into an integrated biopharmaceutical group covering R&D, commercial manufacturing, and marketing. Having evolved from a follower to a peer—and now a leader—in the vaccine industry, CanSinoBIO continues to expand its international footprint. The company’s quality management system has consistently met global standards, with products now present in more than ten overseas markets, including localized production in Indonesia and Mexico.

Prof. Taruna Ikrar commended CanSinoBIO for its achievements in innovation, R&D, and quality system development. He noted that the Indonesian BPOM attaches great importance to vaccine technology transfer and the supervision of novel vaccines, expressing hope that this visit would further strengthen cooperation in R&D, registration, and quality standards; accelerate the realization of joint outcomes; and contribute to regional public health.

Indonesian BPOM’s delegation also visited CanSinoBIO’s vaccine base to gain a closer look at its production processes and quality management system in key stages such as formulation, filling, and packaging. Prof. Ikrar spoke highly of the company’s advanced manufacturing capabilities and rigorous quality control, expressing anticipation for deeper collaboration in innovative vaccine development.

CanSinoBIO shared updates on ongoing collaborations with Indonesian partners in areas including the inhaled tuberculosis vaccine (adenovirus type 5 vector) and the quadrivalent meningococcal conjugate vaccine, as well as the progress of undergoing clinical research, registration, and technology transfer. The company reaffirmed its commitment to working closely with Indonesian partners to advance innovative vaccine programs.

Participants in the meeting included Cui Huisu, Director of the Supervision Division of Tianjin Medical Products Administration; Yan Dong, Director of the Registration Division of Tianjin Medical Products Administration; Wang Yongjiang, Dr. William Adi Tej Deputy of Drugs, Narcotics, Psychotropics, Precursors, and Addictive Substances Control of the Indonesian BPOM; Dr. Lynda Kurnia Wardhan, Head of Bureau of Cooperation and Public Relations of the Indonesian BPOM; Singgih Prabowo Adi, Staff of Indonesian BPOM; Nathan Tirtana, CEO of Etana; as well as Dr. Shoubai CHAO, Chief Operating Officer of CanSinoBIO; Dr. Tao ZHU, Chief Scientific Officer; Jeanne WANG, Chief Commercial Officer; and Wang Hongyi, Vice President and Head of International Business.

As of today, CanSinoBIO’s quadrivalent meningococcal conjugate vaccine has been officially registered in Indonesia. The company’s inhaled tuberculosis vaccine (adenovirus type 5 vector) and recombinant poliovirus vaccine (CS-2036) have also received clinical trial approvals in Indonesia.